HAVEN 2 Updated Analysis: Multicentre, Open-label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab Prophylaxis in Paediatric Patients with Haemophilia A with Inhibitors

被引：0
|
作者：
Young, G. [1 ]
Sidonio, R. F. [2 ,3 ]
Liesner, R. [4 ]
Oldenburg, J. [5 ]
Chang, T. [6 ]
Uguen, M. [7 ]
Dhalluin, C. [7 ]
Schmitt, C. [7 ]
Levy, G. G. [6 ]
Shima, M. [8 ]
Mahlangu, J. [9 ]
机构：
[1] Univ Southern Calif, Keck Sch Med, Childrens Hosp Los Angeles, Los Angeles, CA USA
[2] Emory Univ, Atlanta, GA 30322 USA
[3] Childrens Healthcare Atlanta, Atlanta, GA USA
[4] Great Ormond St Hosp Sick Children, London, England
[5] Univ Klinikum Bonn, Bonn, Germany
[6] Genentech Inc, San Francisco, CA USA
[7] F Hoffmann La Roche Ltd, Basel, Switzerland
[8] Nara Med Univ Hosp, Kashihara, Nara, Japan
[9] Univ Witwatersrand, Johannesburg, South Africa
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2018年 / 181卷
关键词：
emicizumab; haemophilia A; inhibitors; paediatric;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BSH18-OR-0
引用
收藏
页码：20 / 21
页数：2
相关论文
共 50 条
  • [41] Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors
    Gordon, Michael S.
    Nemunaitis, John
    Barve, Minal
    Wainberg, Zev A.
    Hamilton, Erika P.
    Ramanathan, Ramesh K.
    Sledge, George W., Jr.
    Yue, Huibin
    Morgan-Lappe, Susan E.
    Blaney, Martha
    Kasichayanula, Sreeneeranj
    Motwani, Monica
    Wang, Lan
    Naumovski, Louie
    Strickler, John H.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (10) : 1988 - 1995
  • [42] A PHASE 4, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF SUBCUTANEOUS AZACITIDINE IN ADULT TAIWANESE SUBJECTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES
    Chou, W. C.
    Yeh, S. P.
    Hsiao, L. T.
    Lin, S. F.
    Chen, Y. C.
    Chen, T. Y.
    Wang, J. Y.
    Galettis, A.
    Dong, Q.
    Songer, S.
    Beach, C.
    HAEMATOLOGICA, 2014, 99 : 612 - 612
  • [43] Pharmacokinetics, Efficacy and Safety Evaluation of FRSW107 in Previously Treated Hemophilia a Patients: A Multicentre, Open-Label, Non-Randomized Phase III Study
    Xue, Feng
    Zhou, Hu
    Chen, Yun
    Sun, Jing
    Zeng, Xiaojing
    Jin, Chenghao
    Lei, Pingchong
    Li, Zhenyu
    Xi, Yaming
    Sun, Lirong
    Cui, Zhongguang
    Zhao, Xielan
    Yang, Linhua
    Zhang, Bangshuo
    Shen, Aizong
    Wu, Runhui
    Wang, Xiaolin
    Liu, Ling
    Wang, Yuhua
    Sun, Lizhi
    Xia, Yan
    Mo, Weichuan
    Yuan, Dong
    Lou, Jiwei
    Gan, Taiping
    Hu, Chengli
    Ling, Chen
    Su, Hongsheng
    Wang, Yali
    Tang, Baolin
    Yang, Renchi
    BLOOD, 2022, 140 : 8468 - 8469
  • [44] Safety and efficacy of prophylaxis and on-demand treatment with BAY 94-9027: results of a phase 2/3 multicentre, partially randomized, open-label trial
    Reding, Mark
    Powell, Jerry
    Santagostino, Elena
    Ng, Heng Joo
    Lederman, Mel
    Wang, Maria
    Walsch, Rene
    Sax, Mirjam
    Michaels, Lisa A.
    HAEMOPHILIA, 2014, 20 : 20 - 20
  • [45] Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease
    Doody, RS
    Geldmacher, DS
    Gordon, B
    Perdomo, CA
    Pratt, RD
    ARCHIVES OF NEUROLOGY, 2001, 58 (03) : 427 - 433
  • [46] Efficacy and safety of lanadelumab in Japanese patients with hereditary angioedema: A phase 3 multicenter, open-label study
    Hide, Michihiro
    Ohsawa, Isao
    Nurse, Christina
    Yu, Ming
    JOURNAL OF DERMATOLOGY, 2023, 50 (11): : 1381 - 1391
  • [47] DosEmi study protocol: a phase IV, multicentre, open-label, crossover study to evaluate non-inferiority of pharmacokinetic-guided reduced dosing compared with conventional dosing of emicizumab in people with haemophilia A
    Donners, Anouk
    van der Zwet, Konrad
    Egberts, Antoine C. G.
    Fijnvandraat, Karin
    Mathot, Ron
    Kruis, Ilmar
    Cnossen, Marjon H.
    Schutgens, Roger
    Urbanus, Rolf T.
    Fischer, Kathelijn
    BMJ OPEN, 2023, 13 (06):
  • [48] An open-label, multicentre phase 3 study evaluating lanadelumab for the prevention of hereditary angioedema attacks in paediatric patients: SPRING study design
    Farkas, H.
    Lumry, W. R.
    Li, H. H.
    Tachdjian, R.
    Aygoren-Pursun, E.
    Lu, P.
    Nurse, C.
    Pedrosa, M.
    ALLERGY, 2020, 75 : 467 - 468
  • [49] A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared with Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera
    Gotlib, Jason
    Gabrail, Nashat
    O'Connell, Casey L.
    Garcia-Delgado, Regina
    Sbardellati, Timothy
    Rothbaum, Wayne M.
    McGreivy, Jesse
    Harrison, Claire N.
    Kiladjian, Jean-Jacques
    BLOOD, 2019, 134
  • [50] Garadacimab For Hereditary Angioedema Prophylaxis In Adolescents: Efficacy And Safety From The Phase 3 (VANGUARD) Study And Open-Label Extension (Second Interim Analysis)
    Jacobs, Joshua
    Magerl, Markus
    Martinez-Saguer, Inmaculada
    Li, Huamin
    Bernstein, Jonathan
    Hsu, Connie
    Sitz, Karl
    Wieman, Lolis
    Feuer-Senger, Henrike
    Pollen, Maressa
    Reshef, Avner
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB6 - AB6
12345